3.88
price down icon2.14%   -0.0849
after-market After Hours: 3.56 -0.32 -8.25%
loading
Titan Pharmaceuticals Inc De stock is traded at $3.88, with a volume of 48,258. It is down -2.14% in the last 24 hours and down -3.72% over the past month.
See More
Previous Close:
$3.9649
Open:
$3.965
24h Volume:
48,258
Relative Volume:
1.94
Market Cap:
$3.55M
Revenue:
$61,000
Net Income/Loss:
$-6.17M
P/E Ratio:
-6.807
EPS:
-0.57
Net Cash Flow:
$-6.43M
1W Performance:
+0.52%
1M Performance:
-3.72%
6M Performance:
-40.40%
1Y Performance:
-42.94%
1-Day Range:
Value
$3.64
$4.2947
1-Week Range:
Value
$3.55
$4.2947
52-Week Range:
Value
$3.51
$14.80

Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile

Name
Name
Titan Pharmaceuticals Inc De
Name
Phone
(650) 244-4990
Name
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
Employee
0
Name
Twitter
@titanpharma
Name
Next Earnings Date
2024-06-28
Name
Latest SEC Filings
Name
TTNP's Discussions on Twitter

Compare TTNP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
3.88 3.55M 61,000 -6.17M -6.43M -8.20
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
463.98 119.49B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
754.26 82.89B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
624.96 37.37B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.72 32.85B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
114.70 27.50B 3.30B -501.07M 1.03B -2.1146

Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-26-19 Initiated Maxim Group Buy
Nov-10-17 Downgrade ROTH Capital Buy → Neutral

Titan Pharmaceuticals Inc De Stock (TTNP) Latest News

pulisher
Nov 27, 2024

Titan Pharmaceuticals faces Nasdaq compliance issues - Investing.com

Nov 27, 2024
pulisher
Nov 27, 2024

Titan Pharmaceuticals Faces Double Nasdaq Compliance Challenge Over Filing, Audit Issues | TTNP Stock News - StockTitan

Nov 27, 2024
pulisher
Nov 22, 2024

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan

Nov 22, 2024
pulisher
Nov 21, 2024

Conduit Pharma Secures Key Patent for Autoimmune Drug AZD1656 in Major Japan Market | CDT Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals Appoints Former Eisai CEO Ivan Cheung to Board of Directors | LXRX Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 20, 2024

Melt Pharma's MELT-300 Shows Breakthrough Results in Phase 3 Sedation Trial | HROW Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 19, 2024

Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 19, 2024

Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 15, 2024

Virpax Pharmaceuticals Raises $5M to Advance Pain Management Drug Development | VRPX Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 14, 2024

Elite Pharmaceuticals Revenue Surges 33% to $18.9M, Operating Profit Jumps 84% | ELTP Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

TFF Pharmaceuticals Announces Complete Shutdown, Appoints Wind-Down Specialist as CEO | TFFP Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Universe Pharmaceuticals Announces 15:1 Reverse Stock Split Amid NASDAQ Concerns | UPC Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Citius Phase 1 Trial Shows 27% Response Rate with LYMPHIR-Keytruda Combo in Cancer Study | CTXR Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 08, 2024

InMed Announces 1-for-20 Reverse Split to Maintain Nasdaq Listing | INM Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 07, 2024

NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Elite Pharmaceuticals (ELTP) to Host Q2 FY2025 Earnings Call on November 15 | ELTP Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Bionoid Pharma Unveils 5-Year AI-Powered Growth Strategy, Targets 15% EBITDA | BINP Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Acadia Pharma Sells FDA Priority Review Voucher for $150M, Boosts R&D Pipeline | ACAD Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline | CDT Stock News - StockTitan

Nov 04, 2024
pulisher
Nov 01, 2024

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - StockTitan

Nov 01, 2024
pulisher
Oct 31, 2024

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan

Oct 30, 2024
pulisher
Oct 29, 2024

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan

Oct 29, 2024
pulisher
Oct 28, 2024

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 - StockTitan

Oct 28, 2024
pulisher
Oct 28, 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 - StockTitan

Oct 28, 2024
pulisher
Oct 24, 2024

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call - StockTitan

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - StockTitan

Oct 24, 2024
pulisher
Oct 24, 2024

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib) - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan

Oct 23, 2024

Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.65
price down icon 0.23%
$74.62
price up icon 3.60%
$41.63
price down icon 2.23%
$374.40
price up icon 1.52%
$199.09
price down icon 3.36%
$114.70
price down icon 0.77%
Cap:     |  Volume (24h):